On November 22, 2022 (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, reported that Janux management will present at two upcoming investor conferences and be available for 1×1 meetings (Press release, Janux Therapeutics, NOV 22, 2022, View Source [SID1234624369]). Details of the presentations are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Piper Sandler 34th Annual Healthcare Conference
Date: Tuesday, November 29
Time: 8:50am to 9:10am Eastern Time
Forum: Company Presentation
Location: New York, NY

5th Annual Evercore ISI HealthCONx Conference
Dates: Wednesday, November 30
Time: 12:35pm to 12:55pm Eastern Time
Forum: Virtual Fireside Chat